With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.
In his Nobel Prize acceptance speech in 1980, genomics pioneer Fred Sanger described science as “a voyage of discovery into ...
Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are IDEXX ...
Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: Focus on Application, Technology, Offering, End User, and Regional ...
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...
A research team has uncovered and reconstructed the complete biosynthetic pathway of polyphyllin II—a potent anticancer ...
Zacks.com on MSN
Three Genomics Stocks Worth Tracking This Year
An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...
Making is Fueling Strong Growth in Pan-Genomic and Multi-Gene Panel Testing, Supported by Expanding NGS Access, Advanced ...
Researchers from the Faculty of Engineering at The University of Hong Kong (HKU) have developed two innovative deep-learning ...
Jan 13 (Reuters) - Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help ...
Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results